Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

X4 Pharmaceuticals Inc

XFOR ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Small Cap Analyst: STRONG BUY

Last Close

$3.51

▼ -13.24%

Market Cap $347.51M · Vol 411.48K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$347.51M

Small Cap

Div Yield

N/A

EPS Growth

+64.28%

YoY

RSI (14)

19.74

Momentum

Beta

0.43

vs Market

52W High

$4.83

27.36% below

52W Low

$2.80

25.18% above

Volume

411.48K

Avg 189.79K

P/B

1.95

Price-to-book

ROE

-75.99%

Return on equity

Free Float

91.49%

Public shares

Shariah Compliance8 STANDARDS

✗ X4 Pharmaceuticals Inc (XFOR) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does XFOR pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-13.24%

-24.46%

-5.53%

-6.78%

YTD

-12.38%

+3.39%

-90.42%

-97.57%

Financials & Valuation

TTM · Annual

Total Revenue	$35.11M
Net Income	$-79,199,000.00
Revenue Growth (YoY)	+346.33%
Gross Margin	83.60%
Operating Margin	-247.44%
Net Profit Margin	-225.55%
ROE	-75.99%
ROA · ROIC	-36.24% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	4.82
P/B	1.95
P/FCF	N/A
EPS Growth	+64.28%
Outstanding Shares	99.15M

Technical Indicators

50-Day SMA	$4.07
200-Day SMA	$3.94
RSI (14)	19.74
Beta	0.43
52-Week High	$4.83
52-Week Low	$2.80

Volume Today	411.48K
Avg Daily Volume (30D)	189.79K
Relative Volume	2.17x
Volatility (10D)	72.87
Volatility (30D)	63.75
Free Float	91.49%

Analyst Consensus

STRONG BUY

Current Price $3.51

Mean Target $11.60

52W Low$2.80 52W High$4.83

Current

Target

$2.80 $4.83

Current Analyst target

+230.96% upside potential · 5 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001TCY1B7

ISINUS98420X2027

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.21% JNJ Johnson & Johnson -2.22% ABBV Abbvie Inc -2.99% NVS Novartis AG -13.93% NOVN.S Novartis AG -10.89%

Company Profile

X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.